Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Quick facts

Phase 1 pipeline

• EXS73565
• GTAEXS617

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. portfolio CI brief
• Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. pipeline updates RSS